Jiangsu Hengrui Pharmaceuticals Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Lianyungang, Jiangsu and currently employs 20,238 full-time employees. The company went IPO on 2000-10-18. Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company mainly engaged in the research, development, production and sales of drugs. The firm focuses on the field of oncology, covering kinase inhibitors, antibody-drug conjugates (ADCs), tumor immunity, hormone receptor regulation, deoxyribonucleic acid (DNA) repair and epigenetics, supportive care and other research areas. The firm's products include anti-tumor, analgesic anesthesia and contrast agents, which are used in autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, blood diseases, pain management, neurological diseases, ophthalmology, nephrology and other fields. The firm mainly conducts its businesses in domestic and foreign markets.
01276.HK stock price ended at $70.6 on 木曜日, after rising 0.71%
On the latest trading day Feb 12, 2026, the stock price of 01276.HK rose by 0.71%, climbing from $70.00 to $70.60. During the session, the stock saw a volatility of 2.86%, with prices oscillating between a daily low of $70.00 and a high of $72.00. Notably, trading volume dropped by 24.7K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 2.5M shares were traded, equating to a market value of approximately $18.2B.